Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 2/20 | 0.41 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21244224 | 0.85 | CDC7 (0.41) | ALDH1A1HCAR2FFAR2NPSR1NCOA1 | |
| SCHEMBL14164243 | 0.85 | HCAR2 (0.50) | ALDH1A1HCAR2FFAR2NPSR1NCOA1 | |
| SCHEMBL21448921 | 0.83 | FFAR2 (0.43) | ALDH1A1HCAR2FFAR2NPSR1NCOA1 | |
| SCHEMBL5196234 | 0.83 | FFAR2 (0.40) | ALDH1A1HCAR2FFAR2NPSR1NCOA1 | |
| SCHEMBL472995 | 0.82 | CSNK2A2 (0.42) | ALDH1A1HCAR2FFAR2NPSR1NCOA1 | |
| SCHEMBL600887 | 0.82 | HCAR2 (0.61) | ALDH1A1HCAR2FFAR2RAB9ASMN1; SMN2 | |
| SCHEMBL4292895 | 0.78 | HCAR2 (0.42) | ALDH1A1HCAR2FFAR2NPSR1NCOA1 | |
| SCHEMBL1107386 | 0.78 | HCAR2 (0.68) | ALDH1A1HCAR2FFAR2NPSR1NCOA1 | |
| SCHEMBL23146191 | 0.77 | HCAR2 (0.41) | ALDH1A1HCAR2FFAR2NPSR1NCOA1 | |
| SCHEMBL2583653 | 0.77 | ALDH1A1 (0.49) | ALDH1A1HCAR2FFAR2NPSR1NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119241530-A | Tovorafenib medicine synthesis process | 武汉九州钰民医药科技有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-12129249-B2 | Method for producing optically active compound | DAY ONE BIOPHARMACEUTICALS, INC. (US) | 2024-10-29 | — | — | US | disclosed |
| EP-4406609-A2 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | Day One Biopharmaceuticals, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| CN-117447464-A | Method for producing optically active compound | 首日生物制药公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-111032047-B | Method for producing optically active compound | 多特疗法-1公司 | 2023-10-27 | — | — | CN | disclosed |
| US-20210347769-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DAY ONE BIOPHARMACEUTICALS, INC. | 2021-11-11 | — | — | US | disclosed |
| US-20210347769-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DAY ONE BIOPHARMACEUTICALS, INC. | 2021-11-11 | — | — | US | disclosed |
| US-10988469-B2 | Method for producing optically active compound | DOT THERAPEUTICS-1, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-10988469-B2 | Method for producing optically active compound | DOT THERAPEUTICS-1, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200317659-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DAY ONE BIOPHARMACEUTICALS, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20200317659-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DAY ONE BIOPHARMACEUTICALS, INC. | 2020-10-08 | — | — | US | disclosed |
| CN-111032047-A | Process for producing optically active compound | 千年制药公司 | 2020-04-17 | — | — | CN | disclosed |
| EP-3632441-A2 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | Millennium Pharmaceuticals, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-3632441-A2 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | Millennium Pharmaceuticals, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| CN-101921268-B | 5-thiazole amide compound and biological applications | 中山大学肿瘤防治中心 | 2016-08-03 | — | — | CN | disclosed |
| CN-101921268-A | 5-thiazole amide compound and biology application thereof | UNIV SUN YAT SEN CANCER CT | 2010-12-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988469-B2 | Method for producing optically active compound | DHPS, QDPR, SPR | ALDH1A1 1036/4885HCAR2 3810/4885FFAR2 4259/4885 |
| US-20200317659-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DHPS, QDPR, SPR | ALDH1A1 1036/4885HCAR2 3810/4885FFAR2 4259/4885 |
| US-12129249-B2 | Method for producing optically active compound | DHPS, QDPR, SPR | ALDH1A1 1036/4885HCAR2 3810/4885FFAR2 4259/4885 |
| US-20210347769-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DHPS, QDPR, SPR | ALDH1A1 1036/4885HCAR2 3810/4885FFAR2 4259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.